(Hotel) Beijing, China Registration Hotline: +86 (21) 2326 3680 www.ibcchina.com.cn/worldcancer www.ibcchina.com.cn Distinguished VIP Speakers 特别VIP演讲嘉宾 20 – 22 November, 2008, Beijing International Hotel, China 2008年11月20-22日,中国北京国际饭店 Prof Huang Jie-fu, Vice Minister Ministry of Public Health China Distinguished Expert for Live Transplantation Dr Kong Ling Zhi, Deputy Director Ministry of Health Disease Control & Prevention Bureau 黄洁夫教授 中华人民共和国卫生部副部长 著名肝移植专家 孔灵芝博士 中华人民共和国卫生部疾病预防控制局副局长 Keynote Presentations from: Prof He Jie, Chief of Thoracic Surgical Oncology, Vice President, Cancer Institute & Hospital, Chinese Academy of Medical Sciences Prof David Khayat, Chief of Medical Oncology, Pitié-Salpêtrière Hospital & former President, French National Cancer Institute Prof Nagahiro Saijo, President, International Association for Study of Lung Cancer & President, Japanese Society of Medical Oncology & Deputy Director, National Cancer Center Hospital East, Japan Prof Mario Dicato, Hematologist-Oncologist & Chairman, Centre Hospitalier de Luxembourg Prof Mohandas Mallath, Head of Dept. Digestive Diseases & Clinical Nutrition, Tata Memorial Hospital, Dean-Academic, Tata Memorial Centre, India Prof John Milburn Jessup, Chief of Diagnostics Evaluation Branch, Cancer Diagnosis Program, DCTD, National Cancer Institute, USA 主题演讲人: 赫捷教授, 中国医学科学院肿瘤医院肿瘤研究所副院所长,肺癌中心主任 David Khayat 教授, 法国萨伯特慈善医院(Pitié-Salpêtrière Hospital)肿瘤科主任; 法国国家癌症研究 中心前任主席 Nagahiro Saijo 教授, 日本千叶市国立癌症医院副院长, 国际肺癌协会主席,日本内科肿瘤学会主席 Mario Dicato 教授, 卢森堡公国癌症研究中心主席, 血液肿瘤专科医师 Mohandas Mallath 教授, 印度塔塔纪念医院消化及临床营养科主任, 塔塔癌症研究中心学术院长 John Milburn Jessup 教授, 美国国家癌症研究所癌症治疗与诊断中心诊断项目审核部主任 New in 2008: • Updates on cancer epidemic & control strategy in Asia & China • New approaches and strategies to diagnose and treat cancer • Hear from clinical practitioners to understand current status & future trends for cancer therapy • Learn from international experts to improve patient life quality with supportive care • Focus on clinical research & evaluate technical developments in exploratory medicine 2008 年会议关注主题 • 亚洲肿瘤病症流行趋势与政府预防控制计划第一 手信息跟进 • 癌症治疗与生物学诊断的最新研究和实践 • 聆听来自临床实践者经验分享,了解癌症疗法的 现状与发展应用动向 • 留心国际专家最新研究,运用支持治疗改善病患 生活境遇 • 关注临床研究,总结获取最新探索性抗癌药物的 研究方法 2nd Annual International Congress Cancer Prevention, Diagnostics & Treatment 癌症的预防控制、病症诊断及临床治疗 Approved By 批准单位: Supporting association Organised by 主办方: Presented by 运作代表机构:
Transcript
(Hotel) Beijing, China
Registration Hotline:
+86 (21) 2326 3680
www.ibcchina.com.cn/worldcancer
www.ibcchina.com.cn
Distinguished VIP Speakers 特别VIP演讲嘉宾
20 – 22 November, 2008, Beijing International Hotel, China2008年11月20-22日,中国北京国际饭店
Prof Huang Jie-fu, Vice Minister Ministry of Public Health China Distinguished Expert for Live Transplantation
Dr Kong Ling Zhi, Deputy Director Ministry of Health Disease Control & Prevention Bureau
黄洁夫教授中华人民共和国卫生部副部长著名肝移植专家
孔灵芝博士中华人民共和国卫生部疾病预防控制局副局长
Keynote Presentations from:
Prof He Jie, Chief of Thoracic Surgical Oncology, Vice President, Cancer Institute & Hospital, Chinese Academy of Medical Sciences
Prof David Khayat, Chief of Medical Oncology, Pitié-Salpêtrière Hospital & former President, French National Cancer Institute
Prof Nagahiro Saijo, President, International Association for Study of Lung Cancer & President, Japanese Society of Medical Oncology & Deputy Director, National Cancer Center Hospital East, Japan
Prof Mario Dicato, Hematologist-Oncologist & Chairman, Centre Hospitalier de Luxembourg
Prof Mohandas Mallath, Head of Dept. Digestive Diseases & Clinical Nutrition, Tata Memorial Hospital, Dean-Academic, Tata Memorial Centre, India
Prof John Milburn Jessup, Chief of Diagnostics Evaluation Branch, Cancer Diagnosis Program, DCTD, National Cancer Institute, USA
主题演讲人:
赫捷教授,中国医学科学院肿瘤医院肿瘤研究所副院所长,肺癌中心主任
David Khayat教授,法国萨伯特慈善医院(Pitié-Salpêtrière Hospital)肿瘤科主任;法国国家癌症研究中心前任主席
• Updates on cancer epidemic & control strategy in Asia & China
• New approaches and strategies to diagnose and treat cancer
• Hear from clinical practitioners to understand current status & future trends for cancer therapy
• Learn from international experts to improve patient life quality with supportive care
• Focus on clinical research & evaluate technical developments in exploratory medicine
2008年会议关注主题
• 亚洲肿瘤病症流行趋势与政府预防控制计划第一手信息跟进
• 癌症治疗与生物学诊断的最新研究和实践
• 聆听来自临床实践者经验分享,了解癌症疗法的现状与发展应用动向
• 留心国际专家最新研究,运用支持治疗改善病患生活境遇
• 关注临床研究,总结获取最新探索性抗癌药物的研究方法
2nd Annual International Congress
Cancer Prevention, Diagnostics & Treatment癌症的预防控制、病症诊断及临床治疗
Approved By 批准单位: Supporting association
Organised by 主办方:
Presented by 运作代表机构:
REGISTER Today! Call our customer service today to reserve your place at this event Tel +86 21 2326 3680 or email [email protected]
Researchers, Professors & Clinical Doctors From:Cancer Institute(Hospital), Chinese Academy of Medical Science • Beijing Stomatological Hospital •Guangdong Provincial People’s Hospital • Fudan University Cancer Hospital, China • Peking Union Medical College • Beijing Ludaopei Hospital • Sun Yat-Sen University, China • Guangzhou Changxing Hospital • M.D Andersen Cancer Center, USA • Children’s Medical Research Institute, Australia • Kyung Hee University, Korea • GAZIANTEP University, Turkey • National University of Singapore • National Chung Hsing University, Taiwan • Nagoya City University, Japan etc...
Industry Professionals & Scientists From:AstraZeneca • Roche • Merck Sharp & Dohme • Novo Nordisk • IMS Health Asia • TTY BIOPHARMA • HuaDong Medicine • Hengrui Pharma • Medigreen Biotechnology • Egret Pharma • Edding Pharma • Asia Pacific Pharmaceutical Holding • Albany Molecular Centre • BioVeda • Beijing Honghui Meditech etc...
Asia’s prevalence of cancer deaths may climb 45% to 163 per 100,000 people by 2030, from about 112 per 100,000 in 2005. At that rate it would overtake the Americas, where cancer-related mortalities are expected to rise to 156 per 100,000 from 136 over the same period. Europe, which has the highest prevalence at 215 per 100,000, may increase by 9% to 234 per 100,000.
In China, the cancer rate was close to that of the US, Britain and France, which is much higher than its Asian neighbours including Japan, India and Thailand. About 80% of cancer patients perished from common cancers of the lungs, liver and stomach.
Related spending on prevention and treatment is increasing rapidly, presenting a critical challenge for public healthcare system. With support from the Ministry of Public Health China, the World Cancer Conference (WCC) was developed to bring international cancer expertise to Asia for top level knowledge exchange in the region.
On behalf of the organizers, Informa Healthcare & PMPH, we sincerely welcome cancer researchers, clinical doctors and medical professionals to this exciting meeting, to bring the latest medical science and research, understand new technologies in cancer treatment and improve cancer care in China & beyond.
We looking forward to welcoming you to Beijing in November.
Cancer already kills more people worldwide than AIDS, tuberculosis and malaria combined.
Sponsorship and Exhibition OpportunitiesIBC has a consistent reputation in gathering senior professionals & decision makers from the healthcare industry for knowledge sharing & networking. Product & service exhibitions are also a key part of our program. World Cancer Conference provides your business with rewarding market positioning and unlimited new business development opportunities Maximise your presence with a number of lead-generating, networking, and branding packages including:
Present A Poster At This Event!Would you like to share your research with your peers and the key industry leaders in healthcare?
Poster sessions offer you a unique opportunity to have your scientific research projects displayed at this conference and exhibition, to be reviewed by your peers.
Submitting Your AbstractYou must be registered as a delegate to present a poster. To apply, please submit your abstract of 200 words or less, written in English, listing the principal author and full contact details (organisation, mailing address, E-mail, phone, fax, poster, title, additional authors) to Kelvin Ho at [email protected]
Last date for submission of posters is 12 October 2008. In order to secure the Poster Board, a fee of US$100/CNY700 will be required.
World Cancer Conference 国际肿瘤大会
World Cancer Conference 国际肿瘤大会
Day One | Thursday 20th November, 2008
Cancer Prevention, Diagnostics & Treatment 癌症的预防控制、病症诊断及临床治疗
Cancer Prevention, Diagnostics & Treatment 癌症的预防控制、病症诊断及临床治疗
08:00 Morning coffee and registration
08:30 Welcome from organiser
08:35 Chairman Opening remarks
08:45 Opening address from Guest of Honour
Prof Huang Jie-Fu, Vice Minister, Ministry of Public Health, China
CANCER CONTROL & TREATMENT DEVELOPMENTS
09:00 Organ transplant- development as a novel treatment for liver cancer• Overview of liver transplants in Asia: past experience, current
status & future developments• Combining radiation, chemotherapy with liver transplant to
improve survival rates• Pre-surgery evaluation: key factors for the decision making process• LDLT for liver cancer treatment in ChinaProf Huang Jie-Fu, Vice Minister, Ministry of Public Health, China
09:35 Overview of cancer disease control & prevention initiatives in China• Epidemiology overview of cancer disease in China• Government initiatives for cancer prevention, diagnosis
& treatment• Public private partnership practice for cancer control in China Kong Ling Zhi, Deputy Director of Disease Control Department, Ministry of Public Health, China
10:10 International perspective: Cancer Control in France & the War on Cancer Plan 2003-2008
Prof David Khayat, Head of Medical Oncology, Salpetriere Hospital & Former President, French National Cancer Institute
10:45 Morning refreshment & poster/exhibition viewing time
EPIDEMIOLOGY & PREVENTION
11:15 Epidemiology and prevention of hepatitis associated hepatocellular carcinoma – a worldwide translational approach
A meta-analysis on the seroprevalence of HBsAg and anti-HCV antibodies in 27 881 hepatocellular carcinomas from 90 studies confirmed wide international variations. A predominance of HBsAg was found in hepatocellular carcinomas from most Asian, African and Latin American countries, but anti-HCV predominated in Europe, North America, Japan, Pakistan, Mongolia, and Egypt. Anti-HCV was found more often than HBsAg in Europe and the United States. 25 years after having been licensed, HBV vaccination programs are now carried out in 158 countries, but they have yet to reach many high-risk populations in sub-Saharan Africa and Asia. In the absence of a vaccine, the prevention of HCV infection requires an integrated strategy (ie, screening of blood donations, safe injection practices and avoidance of unnecessary injections).Syed Ahsan Raza, MD MSc, Senior Instructor, Research Department of Surgery, The Aga Khan University
11:50 The modulating role 5-LOX in the carcinogenic action of cigarette smoke and its active component in colon cancer
Substantial evidence indicates that cigarette smoke exposure is a risk factor for colorectal cancer. We investigated the modulating role of cigarette smoke and its active component NNK, in 5-LOX expression and expression of 5-LOX in SW1116 colon cancer cells. It also promoted 5-LOX DNA de-methylation. NNK stimulated colon cancer cell proliferation, enhanced α7-nAChR mRNA level, NF-қB DNA binding activity, 5-LOX and COX-2 expression. Inhibitors of COX-2 and 5-LOX inhibited tumor growth in nude mice. The present study demonstrates the central role of 5-LOX in the carcinogenic action of cigarette smoke and NNK on colon cancer.Prof Cho Chi Hin, Professor of Pharmacology & Chairman, Department of Pharmacology, Faculty of Medicine, The Chinese University of Hong Kong
12:25 TECHNOLOGY TuTORIAL: Technology and product providers will provide interactive
educational tutorials which address the benefit of their technology or product in the field of cancer diagnostics, prognosis analysis & treatment development. If you would like to host a tutorial, please contact [email protected]
12:45 Luncheon & poster/exhibition viewing time
DISEASE MANAGEMENT & TREATMENT INNOVATION I
14:00 Advances in Surgical Management of Esophageal Cancer Esophageal Cancer is one of the most common cancer types in
China and fourth killer of cancer in Chinese population. Even there are quite a lot of new drugs & therapies developed in this area, surgical operation is still the most mature treatment for esophageal carcinoma. In the session, Dr He Jie will share you his research & insights in surgical management of this common disease in Asia.Prof He jie, Chief of Thoracic Surgical Oncology, Vice President, Cancer Institute & Hospital, Chinese Academy of Medical Sciences
14:35 Treatment for advanced non-small cell lung cancer While there have been advances in the treatment of lung
cancer, they have been marginal with recent advances in the chemotherapy and molecularly targeted treatment of breast, colorectal and genitourinary cancers. Lung cancer is extremely difficult to treat, obtain positive results and develop new standard treatments. The results of clinical trials on gefitinib and erlotinib suggest that the evaluation of molecular target drugs is quite difficult in unselected patient population and may be different from cytotoxic drugs. We need to identify specific molecular biomarkers for each drug. In view of global studies, it will be essential to obtain more significant results by sophisticated clinical trials in selected patient populations and contribute to improving the treatment outcome of lung cancer patients.Prof Nagahiro Saijo, M.D., Ph.D, President, International Association for Study of Lung Cancer; President, Japanese Society of Medical Oncology & Deputy Director, National Cancer Center Hospital East, Japan
15:10 updates and future development of neoadjuvant chemotherapy for breast cancer
Prof Wu Shi Kai, Deputy Director, Department of Breast Cancer, 307 Hospital, Academy of Military Medicine Sciences, China
15:45 Afternoon refreshment & poster/exhibition viewing time
CLINICAL TRIALS IN CHINA
16:15 Phase III/IV clinical trial in China for better treatment• Current regulation guidelines for phase III/IV trial patient
recruitment• Ethical issues in trial design & operation process• Experiences from Western countries
16:50 Clinical challenges of cancer drug combinations• Assessing combination therapies• Obtaining accurate dose response information• Calculating maximum tolerated dosage and biological
effective dosage• Lessons learned from real-life experiences
17:25 Chairman’s remarks & close of conference day 1
17:30 Networking cocktail reception
REGISTER Today! Call our customer service today to reserve your place at this event Tel +86 21 2326 3680 or email [email protected]
Cancer Prevention, Diagnostics & Treatment 癌症的预防控制、病症诊断及临床治疗
Cancer Prevention, Diagnostics & Treatment 癌症的预防控制、病症诊断及临床治疗
REGISTER Today! Call our customer service today to reserve your place at this event Tel +86 21 2326 3680 or email [email protected]
08:30 Morning coffee & tea
DISEASE MANAGEMENT & TREATMENT INNOVATION II
09:00 Progress on advanced colorectal cancer
Prof David Khayat, Head of Medical Oncology, Salpetriere Hospital & Former President, French National Cancer Institute
09:35 Clinical practice advance for liver cancer management
Prof Zhang Yangde, President, National Hepatobiliary & Enteric Surgery Research Center, Ministry of Health
10:10 Treatment development for gastric cancer
Prof Alex Y. Chang, Chief Executive Officer & Medical Director, John Hopkins Singapore International Medical Centre (Invited)
10:45 Morning refreshment & poster/exhibition viewing time
CANCER BIOMARKERS & DIAGNOSTICS
11:15 Development and implementation of assays in cancer care Although increasingly important for targeted and personalized
therapies in the cancer patient, the development and validation of useful biomarkers is often stopped by inadequate assay development. The Cancer Diagnosis Program of the National Cancer Institute has identified multiple needs for assay development that include: specimen acquisition, access to standards and reagents, education on assay development, support for improving assay performance and validation for clinical use. This session will focus on making assays robust and validated for predicting response to therapy and monitoring molecular recurrence.Dr J. Milburn Jessup, Chief of Diagnostics Evaluation Branch, Cancer Diagnosis Program, DCTD, National Cancer Institute, USA
11:50 Circulating tumor cells (CTC) as a prognostic and predictive indicator in advanced lung cancer patients
Scientists have long believed that circulating tumor cells held a wealth of information. This study has shown that negative enrichment immunomagnetic-based technology plays a definitive role in predicting and judging prognosis of lung cancer patients. CTC will go a long way towards addressing an unmet need in the cancer field and could change the course of treatment for many critically ill patients.Prof Zhou Xiao-Yun, Department of Respiratory Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences
12:25 TECHNOLOGY TuTORIAL: Technology and product providers will provide interactive
educational tutorials which address the benefit of their technology or product in the field of cancer diagnostics, prognosis analysis & treatment development. If you would like to host a tutorial, please contact [email protected]
12:45 Luncheon & poster/exhibition viewing time
SUPPORTIVE CARE
14:00 Erythropoietin, where do we stand now?• Controversies 2007-2008• Epo- receptor determination on cancer cells: what do they
imply? Induction of progression of the cancer clone?• How to use erythropoietins in the clinic: advantages and risksDr Mario Dicato, Hematologist-Oncologist, Centre Hospitalier de Luxembourg
14:35 Clinical nutrition support during cancer treatments Malnutrition is the commonest co-morbidity associated with cancer
and a substantial proportion of cancer patients die from cachexia. Patients with cancer in the digestive tract, respiratory tract and head and neck regions are at greatest risk of developing malnutrition. Malnutrition suppresses immunity, delays tissue repair and promotes the loss of muscle mass and hypoproteinemia which results in increased morbidity, mortality, hospital stay and costs. As a result, intensive nutritional support was used to improve the immediate and long term outcomes of cancer treatment. The results of most randomized clinical trials have not been remarkable. Paradoxically, routine use of parenteral nutrition during cytotoxic therapies can result in net harm. Benefit has been demonstrated in preoperative parenteral nutrition in patients undergoing curative surgery for cancer of the upper gastrointestinal tract. In general, all cancer patients should be assessed for malnutrition at initial presentation. At the same time, it is essential that medical and paramedical oncology staff maintain an active interest in nutrition support to ensure maximal benefits from the intervention.Prof Mohandas Mallath, Head of Dept. Digestive Diseases & Clinical Nutrition, Tata Memorial Hospital, & Dean-Academic, Tata Memorial Centre, India
15:10 Afternoon refreshment & poster/exhibition viewing time
ROUND TABLE DISCUSSION
15:40 Emerging technologies & economic realities: can we afford the bill for modern cancer care?
Over the past two decades, new technologies such as PET/CT, radiotherapy, mAbs & biological drugs bring us better hope for cancer treatment. However, the cost of cancer treatment has significantly increased. During this interactive roundtable debate, we will discuss how to implement best therapy to your patient with a cost effective plan.
16:15 Chairman’s remarks & end of conference
Site Tour to TCM Cancer HospitalTCM is part of traditional medical technology development by ancient Chinese. Within thoughts of year development, it has established a unique philosophy & understanding of diseases. Currently, significant advances in research has been conducted in cancer management via TCMs.
The 3 hours tour will provide a preview of how TCM works in China as an alternative therapy for cancer patients.
Attendees will meet at the hotel lobby at 9am and return around 12noon.
Visit Beijing’s “Bird’s Nest” StadiumHost venue of the recently conducted Olympics and spectacular, The “Bird’s Nest” Stadium has became an instant icon of Beijing. View the surrounding area including the Water Cube and visit the stadium on this half day tour.
PMPH Celebrates! Cultural EveningJoin PMPH as it marks its 50th anniversary with an evening performance at Chang’an Theater. Featuring Beijing Opera and traditional Chinese art performance.
有限公司上海分行 Bank Address: No. 1000 Lujiazui Ring Road, Pudong, Shanghai 200120 P. R. China
Payments by US$Payment by telegraphic transfer in US$must be made to:IBC CONFERENCES AND EVENTMANAGEMENT SERVICES (SHANGHAI)CO., LTD.A/C No: 001-396282-056Beneficiary Bank: HSBC Bank (China) Company LimitedBank Address: No. 1000 Lujiazui RingRoad, Pudong, Shanghai 200120P. R. ChinaSwift Code: HSBCCNSH
IMPORTANT NOTE: Please quote the name of the delegate and event title on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Conferences and Events Management (Shanghai) Co., Ltd. will not be responsible for any event re-scheduled or cancelled.
DATA PROTECTION The personal information shown on this brochure, and / or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from, or made available to, external companies for marketing purposes. If you do not wish your details to be used for marketing purposes, please write to our Database Manager, IBC Asia (S) Pte Ltd.
Mail the attached registration form with your cheque to IBC Conferences And Event Management Services (Shanghai) Co.,Ltd Room 3203, LT Square, 500 Chengdu Road North, Shanghai 200003TEL : +86 21 2326 3680FAX : +86 21 5375 0690
5 EASY WAYS TO REGISTER
HOTEL INFORMATION
REGISTER NOW! Fax back to +86 (21) 5375 0690
Please tick I am paying by bank transfer (copy attached) / 我通过银行转帐付款(请见付款凭据复印件)
请在合适项目打勾 Payment by Credit Card / 我通过信用卡付款 请 Amex 请 Visa 请 Mastercard 请 JCB
Ist delegate / 第一名代表 2nd delegate / 第二名代表
Name / 姓名: ____________________________________________ Name / 姓名: ______________________________________________
Post Code / 邮编: ________________________________________ Country / 国家: ____________________________________________
Tel / 电话: _______________________________________________ Fax / 传真: ________________________________________________
Name & Title of Approving Manager / 准予参会的上级姓名与职位: __________________________________________________________
Name & Title of Training Manager / 培训经理的姓名: _______________________________________________________________________
Main Business/Activity / 公司主要业务: __________________________________________________________________________________
Please photocopy for additional delegates
If you have already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.
Cancellations received in writing 10 working days before the event will be entitled to a full refund less 10% administration fee. Thereafter, cancellations are not refundable. Participants may be substituted at any time.
CANCELLATIONS / SUBSTITUTION
I cannot attend this event but / 我不能参加此次会议
Please put me on your mailing list / 我仍希望收到其它相关会议的邀请函
I would like to purchase conference documentation USD565/CNY4,000 per set / 我希望购买此次会议的资料 (USD565/CNY4,000)
Mail the attached registration form with your cheque to IBC Asia (S) Pte Ltd, No. 1 Grange Road, #08-02, Orchard Building, Singapore 239693 CUSTOMER SERVICE TELEPHONE: (65) 6514 3180 / (65) 6732 1970 FAX: (65) 6733 5087 (65) 6736 4312
Beijing International Hotel9 Jianguomennei DaJie, Beijing, China Zipcode: 100005 Tel: (86 -10) 65126688 Hotel room booking, pl contact:Ms. Yang and Mr. [email protected]: +86 10 67711608Fax: +86 10 87713688
To Reserve a Posterboard (Space is limited) 预定大会论文布告板位置 USD$100/CNY700We recommend TT/Wire transfer for payment in US$. For credit card payments, please note that US$ equivalent may vary as the RMB rate will be charged* Academy/Government rate is to full employees of government, universities & university-affiliated hospitals only** All fees are inclusive of a 5.5% Sales Tax. Fee includes luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
Yes! I/We will attend the WORLD CANCER CONFERENCE 20 – 22 November 2008, Beijing, China Yes! I/We will attend the WORLD CANCER CONFERENCE 20 – 21 November 2008, Beijing, China
